(Q36777860)

16 August 2017

1 reference

title

Prevention and management of cytomegalovirus infection in solid-organ transplantation (English)

1 reference

16 August 2017

main subject

organ transplantation

1 reference

based on heuristic

inferred from title

cytomegaloviral disease

1 reference

Kabeya Mwintshi

1

1 reference

16 August 2017

Daniel C Brennan

series ordinal

2

1 reference

16 August 2017

publication date

1 April 2007

1 reference

Expert Review of Anti-infective Therapy

16 August 2017

published in

1 reference

16 August 2017

volume

5

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

295-304

1 reference

New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Prevention and treatment of cytomegalovirus infection in organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Infectious disease complications of renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Simultaneous reconstitution of multiple cytomegalovirus-specific CD8+ cell populations with divergent functionality in hematopoietic stem-cell transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: a 1-yr follow-up of safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: the importance of HLA-DR matching

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Antiviral drugs for cytomegalovirus diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Leflunomide therapy for cytomegalovirus disease in renal allograft recepients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Concurrent antiviral and immunosuppressive activities of leflunomide in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Severing the Gordian knot of prevention of cytomegalovirus in liver transplant recipients: the principle is the sword

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

Combined CMV Prophylaxis Improves Outcome and Reduces the Risk for Bronchiolitis Obliterans Syndrome (BOS) after Lung Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.2.295

21 January 2018

Identifiers

DOI

10.1586/14787210.5.2.295

1 reference

16 August 2017

1 reference